Ibandronsäure Hexal (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to bone mineral and is taken up by osteoclasts during bone resorption. Inside the cell it inhibits the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway, which leads to osteoclast apoptosis and a decrease in bone breakdown.

The dosing regimen for Ibandronsäure Hexal is determined by the prescribing physician based on the patient’s condition, renal function, and other clinical factors. Healthcare professionals set the appropriate dose and infusion schedule for each individual.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Ibandronsäure Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Ibandronsäure Hexal shares the same class mechanism as other bisphosphonates but is administered intravenously, allowing for less frequent dosing compared with oral agents. Its potency in inhibiting bone resorption is comparable to zoledronic acid, while its safety profile and infusion‑related reactions are similar to other IV bisphosphonates.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original packaging until use to maintain stability and potency.

Ibandronsäure Hexal is given as an intravenous infusion. The solution is administered by a qualified healthcare professional, typically over a short period (e.g., 15–30 minutes), following standard aseptic techniques and patient monitoring guidelines.

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, severe renal impairment, and life‑threatening hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of these conditions, especially during the first few infusions.

Ibandronsäure Hexal is contraindicated in patients with known hypersensitivity to ibandronic acid or any component of the formulation, and in those with severe renal impairment (creatinine clearance <30 mL/min). Caution is also advised for patients with existing jaw pathology or recent dental surgery.